Biotech Growth Financials
| BIOG Stock | 867.00 7.00 0.81% |
Biotech | Select Account or Indicator |
Understanding current and past Biotech Growth Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Biotech Growth's financial statements are interrelated, with each one affecting the others. For example, an increase in Biotech Growth's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Biotech Growth's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of The Biotech Growth. Check Biotech Growth's Beneish M Score to see the likelihood of Biotech Growth's management manipulating its earnings.
Biotech Growth Stock Summary
Biotech Growth competes with SANTANDER, and Vodafone Group. Biotech Growth is entity of United Kingdom. It is traded as Stock on LSE exchange.Specialization | Financial Services, Financial Services |
| Instrument | UK Stock View All |
| Exchange | London Exchange |
| ISIN | GB0000385517 |
| Business Address | 601 Lexington Avenue, |
| Sector | Capital Markets |
| Industry | Financials |
| Benchmark | Dow Jones Industrial |
| Website | www.biotechgt.com/index.php/biog/home/over |
| Phone | 212 739 6400 |
You should never invest in Biotech Growth without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Biotech Stock, because this is throwing your money away. Analyzing the key information contained in Biotech Growth's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Biotech Growth Key Financial Ratios
There are many critical financial ratios that Biotech Growth's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Biotech Growth reports annually and quarterly.| Revenue | 80.35 M | ||||
| Gross Profit | (32.42 M) | ||||
| EBITDA | 74.76 M | ||||
| Net Income | 74.6 M | ||||
| Total Asset | 411.42 M |
Biotech Growth Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 649.5M | 427.4M | 360.5M | 411.4M | 473.1M | 314.4M | |
| Other Current Liab | (28.1M) | (32.2M) | (26.4M) | (47.2M) | (42.5M) | (40.4M) | |
| Net Debt | 25.3M | 31.7M | 17.4M | 44.9M | 51.7M | 54.3M | |
| Accounts Payable | 1.4M | 452K | 6.2M | 167K | 150.3K | 142.8K | |
| Total Liab | 48.1M | 33.2M | 30.2M | 50.1M | 57.6M | 60.5M | |
| Total Current Assets | 6.3M | 49K | 3.3M | 16.7M | 19.2M | 20.1M | |
| Common Stock | 10.4M | 10.3M | 9.7M | 8.4M | 7.5M | 10.3M | |
| Retained Earnings | 78.3M | (108.6M) | (51.7M) | (965K) | (868.5K) | (825.1K) | |
| Other Assets | 38K | 35K | 427.4M | 27K | 31.1K | 29.5K | |
| Short Term Debt | 26.8M | 31.7M | 20.2M | 47.1M | 54.1M | 31.7M | |
| Net Tangible Assets | 365.6M | 601.5M | 394.2M | 330.3M | 297.3M | 344.6M | |
| Net Invested Capital | 628.2M | 425.9M | 350.5M | 408.4M | 367.5M | 350.9M | |
| Capital Stock | 10.4M | 10.3M | 9.7M | 8.4M | 7.5M | 8.2M |
Biotech Growth Key Income Statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Expense | 179K | 175K | 792K | 1.1M | 1.3M | 1.3M | |
| Total Revenue | 204.4M | (209.7M) | (37.7M) | 80.3M | 92.4M | 97.0M | |
| Gross Profit | 222.1M | (214.5M) | (43.0M) | 77.2M | 88.8M | 93.3M | |
| Operating Income | 197.3M | (199.8M) | (36.7M) | 76.5M | 88.0M | 92.4M | |
| Ebitda | 3.0M | (10.7M) | (5.3M) | 74.8M | 86.0M | 90.3M | |
| Income Before Tax | 200.6M | (202.3M) | (41.2M) | 74.8M | 86.0M | 90.3M | |
| Net Income | 200.4M | (202.4M) | (41.3M) | 74.6M | 85.8M | 90.1M | |
| Income Tax Expense | 131K | 149K | 56K | 159K | 182.9K | 135.3K | |
| Ebit | 200.4M | (210.5M) | (42.0M) | 151.3M | 136.1M | 142.9M | |
| Tax Provision | 131K | 149K | 56K | 159K | 143.1K | 139.6K | |
| Net Interest Income | (179K) | (172K) | (781K) | (992K) | (892.8K) | (848.2K) | |
| Cost Of Revenue | (17.8M) | 4.8M | 5.3M | 3.1M | 3.6M | 3.8M |
Biotech Growth Key Cash Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Free Cash Flow | (5.7M) | (13.2M) | (5.9M) | (4.2M) | (4.9M) | (5.1M) | |
| Other Non Cash Items | (224.5M) | 208.4M | 35.4M | (78.9M) | (90.8M) | (95.3M) | |
| Net Income | 200.6M | (202.3M) | (41.2M) | 74.6M | 67.1M | 70.5M | |
| Investments | (26.2M) | 14.1M | 45.7M | 22.3M | 20.1M | 23.7M | |
| Net Borrowings | 18.9M | (2.6M) | 2.6M | (15.3M) | (13.8M) | (13.1M) | |
| Change To Netincome | (64.1M) | (224.3M) | 208.5M | 35.5M | 40.8M | 42.9M |
Biotech Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Biotech Growth's current stock value. Our valuation model uses many indicators to compare Biotech Growth value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biotech Growth competition to find correlations between indicators driving Biotech Growth's intrinsic value. More Info.The Biotech Growth is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.57 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for The Biotech Growth is roughly 1.74 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biotech Growth's earnings, one of the primary drivers of an investment's value.Biotech Growth Systematic Risk
Biotech Growth's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Biotech Growth volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Biotech Growth correlated with the market. If Beta is less than 0 Biotech Growth generally moves in the opposite direction as compared to the market. If Biotech Growth Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Biotech Growth is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Biotech Growth is generally in the same direction as the market. If Beta > 1 Biotech Growth moves generally in the same direction as, but more than the movement of the benchmark.
The Biotech Growth Total Assets Over Time
Biotech Growth Thematic Clasifications
The Biotech Growth is part of IT investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Information technology and IT services. Information Technology (IT) companies and IT service providers across different domains
This theme covers Information technology and IT services. Information Technology (IT) companies and IT service providers across different domains. Get More Thematic Ideas
| IT | View |
Biotech Growth January 27, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Biotech Growth help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of The Biotech Growth. We use our internally-developed statistical techniques to arrive at the intrinsic value of The Biotech Growth based on widely used predictive technical indicators. In general, we focus on analyzing Biotech Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Biotech Growth's daily price indicators and compare them against related drivers.
| Information Ratio | (0.22) | |||
| Maximum Drawdown | 6.48 | |||
| Value At Risk | (2.37) | |||
| Potential Upside | 2.11 |
Additional Tools for Biotech Stock Analysis
When running Biotech Growth's price analysis, check to measure Biotech Growth's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biotech Growth is operating at the current time. Most of Biotech Growth's value examination focuses on studying past and present price action to predict the probability of Biotech Growth's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biotech Growth's price. Additionally, you may evaluate how the addition of Biotech Growth to your portfolios can decrease your overall portfolio volatility.